# Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

> **NCT03089775** · PHASE1 · COMPLETED · sponsor: **Fresh Tracks Therapeutics, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Contact Dermatitis

## Interventions

- **DRUG:** BBI-2000
- **DRUG:** Vehicle
- **OTHER:** Multiple treatments

## Key facts

- **NCT ID:** NCT03089775
- **Lead sponsor:** Fresh Tracks Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-14
- **Primary completion:** 2017-05-24
- **Final completion:** 2017-05-24
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03089775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03089775, "Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03089775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*